Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  New England Journal of Medicine

• Publication date

  2006-11-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJMC062506PMID 17108350
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis.

  2006cited by this paper
• Rapid hip bone loss in active Crohn's disease patients receiving short‐term corticosteroid therapy

  2004cited by this paper
• Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies

  2004cited by this paper
• Effect of 1α-vitamin D3 on bone strength and composition in growing rats with and without corticosteroid treatment

  1994cited by this paper
• Bone loss in response to long-term glucocorticoid therapy.

  1990cited by this paper

• Glucocorticoid-induced osteoporosis: novel concepts and clinical implications.

  2025cites this paper
• Assessment of Glucocorticoid-Induced Osteoporosis Treatment by Prevailing Guidelines in a Tertiary Care Hospital

  2025cites this paper
• Bisphosphonate use for glucocorticoid-induced osteoporosis in older patients with immune thrombocytopenia: a clinical perspective

  2023cites this paper
• Glucocorticoid-induced osteoporosis in premenopausal women: management for the rheumatologist

  2023cites this paper
• Argentine Guidelines for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis in Postmenopausal Women and Men Aged 50 Years and Older

  2023cites this paper
• Threshold based on bone mineral density for therapeutic decision-making in postmenopausal women and men over 50 years old under glucocorticoid therapy.

  2022cites this paper
• Bad to the Bone: The Effects of Therapeutic Glucocorticoids on Osteoblasts and Osteocytes

  2022cites this paper
• Risk for osteoporosis and fracture with glucocorticoids.

  2022cites this paper
• Glukokortikoid-induzierte Osteoporose – Fokus Therapie (Teil 2)

  2022cites this paper
• Challenges in the diagnosis and management of glucocorticoid‐induced osteoporosis in younger and older adults

  2021cites this paper
• Glucocorticoid-induced osteoporosis and Cushing’s syndrome

  2021cites this paper
• Glucocorticoid- and Transplantation-Induced Osteoporosis.

  2021cites this paper
• Understanding and Managing Corticosteroid-Induced Osteoporosis

  2021cites this paper
• Efficacy of once-weekly teriparatide for primary prevention of glucocorticoid-induced osteoporosis: A post hoc analysis of the TOWER-GO study.

  2021cites this paper
• Therapeutic Dimensions of Bisphosphonates: A Clinical Update

  2020cites this paper
• Efficacy and safety of 18 anti-osteoporotic drugs in the treatment of patients with osteoporosis caused by glucocorticoid: A network meta-analysis of randomized controlled trials

  2020cites this paper
• Basic and clinical aspects of glucocorticoid action in bone

  2020cites this paper
• Effects of anti-osteoporosis drugs against dexamethasone-induced osteoporosis-like phenotype using a zebrafish scale-regeneration model.

  2020cites this paper
• Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment

  2020cites this paper
• Network pharmacology approach to elucidate possible action mechanisms of Sinomenii Caulis for treating osteoporosis.

  2020cites this paper
• Meta-regression analysis of the efficacy of alendronate for prevention of glucocorticoid-induced fractures

  2020influential citation
• An Overview of Glucocorticoid Induced Osteoporosis-Endotext-NCBI Bookshelf

  2019cites this paper
• Efficacy and Safety of First- and Second-Line Drugs to Prevent Glucocorticoid-Induced Fractures: A Network Meta-Analysis.

  2019cites this paper
• Metabolic Bone Disease in Gastrointestinal Disorders

  2019cites this paper
• Pulsed electromagnetic fields: promising treatment for osteoporosis

  2019cites this paper
• Korean Guideline for the Prevention and Treatment of Glucocorticoid-induced Osteoporosis

  2018cites this paper
• Glucocorticoids and Bone: Consequences of Endogenous and Exogenous Excess and Replacement Therapy.

  2018cites this paper
• University of Birmingham Glucocorticoids and bone: consequences of endogenous and exogenous excess and replacement therapy

  2018cites this paper
• Improvement in Bone Density with Calcitriol Substitution for Cholecalciferol in Refractory Osteoporosis induced by Prednisone

  2018cites this paper
• Effects of alendronate and alfacalcidol on bone in patients with myasthenia gravis initiating glucocorticoids treatment

  2018cites this paper
• An update of the Malaysian Clinical Guidance on the management of glucocorticoid-induced osteoporosis, 2015

  2017cites this paper
• Cost‐effectiveness of bisphosphonates for prevention of fracture related to glucocorticoid‐induced osteoporosis in Malaysia

  2017cites this paper
• Alendronate Sodium in Osteoarthritis: Effects on Lipid Profile, Circulating Leptin and the Clinical Activity

  2017cites this paper
• Promotion effect of extracts from plastrum testudinis on alendronate against glucocorticoid-induced osteoporosis in rat spine

  2017cites this paper
• 2o Curso de Osteoporosis y Enfermedades Metabólicas Óseas para Médicos Residentes

  2017cites this paper
• Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians.

  2017influential citation
• Importancia de los niveles de vitamina d en la prevención secundaria de la osteoporosis corticoidea

  2017cites this paper
• Osteoporosis en enfermedades reumáticas e inducidas por glucocorticoides

  2017cites this paper
• Role of Alendronate and Alfacalcidol in Protection Against Steroid Induced Osteoporosis in Adult Male Albino Rats

  2017cites this paper
• Prophylaxe und Therapie der Glukokortikoid-induzierten Osteoporose

  2017influential citation
• ALENDRONATE SODIUM IN OSTEOARTHRITIS: EFFECTS ON ANABOLIC, CARTILAGE DEGREDATIVE MARKERS AND THE CLINICAL ACTIVITY.

  2017cites this paper
• Vitamin D supplementation for osteoporosis in older adults: can we make it help better?

  2016cites this paper
• Very high frequency of fragility fractures associated with high-dose glucocorticoids in postmenopausal women: A retrospective study

  2016influential citation
• Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials

  2016cites this paper
• Alendronate prevents glucocorticoid-induced osteoporosis in patients with rheumatic diseases

  2016cites this paper
• Can adverse effects of glucocorticoid therapy be prevented and treated?

  2016cites this paper
• Management of osteoporosis in rheumatoid arthritis patients

  2015cites this paper
• Glucocorticoid-induced osteoporosis: who to treat with what agent?

  2015cites this paper
• Management of glucocorticoid-induced osteoporosis: clinical data in relation to disease demographics, bone mineral density and fracture risk

  2015cites this paper
• Bisphosphonates in the treatment of glucocorticoid-induced osteoporosis: pros

  2015cites this paper
• Lipid metabolism disorders and bone dysfunction-interrelated and mutually regulated (Review)

  2015cites this paper
• The value of glucocorticoid co-therapy in different rheumatic diseases - positive and adverse effects

  2014cites this paper
• Pseudopolyarthrite rhizomélique et maladie de Horton

  2014cites this paper
• Minimal Change Disease in Adults

  2014cites this paper
• Glucocorticoid-induced osteoporosis: an overview

  2014cites this paper
• Proteomic Analysis of Gingival Tissue and Alveolar Bone during Alveolar Bone Healing*

  2013cites this paper
• Dynamic Bone Imaging with 99mTc-Labeled Diphosphonates and 18F-NaF: Mechanisms and Applications

  2013cites this paper
• Synergistic antiosteoporotic effect of Lepidium sativum and alendronate in glucocorticoid-induced osteoporosis in Wistar rats.

  2013cites this paper
• Bisphosphonates for the Prevention and Treatment of Osteoporosis in Patients with Rheumatic Diseases: A Systematic Review and Meta-Analysis

  2013influential citation
• Effect of risedronate on bone in renal transplant recipients.

  2012cites this paper
• A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis

  2012cites this paper
• Osteoporosis inducida por glucocorticoides

  2012cites this paper
• Are changes in bone mineral density different between groups of early rheumatoid arthritis patients treated according to a tight control strategy with or without prednisone if osteoporosis prophylaxis is applied?

  2012cites this paper
• Management of Glucocorticoid-Induced Osteoporosis

  2012influential citation
• Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis.

  2012cites this paper
• Age, initial dose and dose increase are independent risk factors for symptomatic vertebral fractures in glucocorticoid-treated male patients.

  2011cites this paper
• [Current indications for prevention and therapy of steroid-induced osteoporosis in men and women].

  2011cites this paper
• Changes in macrophage inhibitory factor correlate with changes in bone mineral density in glucocorticoid-treated patients with rheumatoid arthritis.

  2011cites this paper
• The vitamin D analogue 2MD increases bone turnover but not BMD in postmenopausal women with osteopenia: Results of a 1‐year phase 2 double‐blind, placebo‐controlled, randomized clinical trial

  2011cites this paper
• Review: Ocular side effects of anti-rheumatic medications: what a rheumatologist should know

  2010cites this paper
• Approach to the patient with secondary osteoporosis.

  2010cites this paper
• Efficacy and safety of zoledronic acid in the treatment of glucocorticoid-induced osteoporosis

  2010influential citation
• Management of glucocorticoid-induced osteoporosis: prevalence, and emerging treatment options

  2010cites this paper
• Prevention and treatment of systemic glucocorticoid side effects

  2010cites this paper
• From bone biology to clinical outcome: state of the art and future perspectives

  2010cites this paper
• Efficacy and safety of zoledronic acid in the treatment of glucocorticoid-induced osteoporosis

  2010influential citation
• Zoledronic acid for the treatment and prevention of primary and secondary osteoporosis

  2010cites this paper
• Glucocorticoid-induced osteoporosis: how best to avoid fractures

  2010cites this paper
• Osteoporosis secundaria a fármacos

  2009cites this paper
• Comparison of the Effects of Alendronate and Alfacalcidol on Hip Bone Mineral Density and Bone Turnover in Japanese Men Having Osteoporosis or Osteopenia with Clinical Risk Factors for Fractures

  2009cites this paper
• HIGH PREVALENCE AND EARLY COMPLICATION OF SYMPTOMATIC VERTEBRAL FRACTURE IN ELDERLY PEOPLE TREATED WITH HIGH‐DOSE GLUCOCORTICOIDS

  2009cites this paper
• Effects of Alendronate on Bone Metabolism in Glucocorticoid-Induced Osteoporosis Measured by 18F-Fluoride PET: A Prospective Study

  2009cites this paper
• Clinical trial: comparison of alendronate and alfacalcidol in glucocorticoid‐associated osteoporosis in patients with ulcerative colitis

  2009cites this paper
• Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.

  2009cites this paper
• Glucocorticoid-induced osteoporosis: treatment update and review

  2009cites this paper
• Once-Weekly Oral Alendronate 70 mg in Patients with Glucocorticoid-Induced Bone Loss: A 12-Month Randomized, Placebo-Controlled Clinical Trial

  2009cites this paper
• Bone Loss : A 12-Month Randomized , Placebo-Controlled Clinical Trial Once-Weekly Oral Alendronate 70 mg in Patients with Glucocorticoid-Induced

  2009cites this paper
• Treatment of glucocorticoid-induced osteoporosis

  2009cites this paper
• Age dependence of early symptomatic vertebral fracture with high-dose glucocorticoid treatment for collagen vascular diseases.

  2009cites this paper
• Incidence of symptomatic vertebral fracture with high-dose glucocorticoid treatment in the Chiba-Shimoshizu Rheumatic Cohort between 1986 and 2006.

  2009cites this paper
• Bone protective therapy in the young patient with fractures and chronic disease: what drug(s) should be given and for how long?

  2009cites this paper
• Notable difference between the development of vertebral fracture and osteonecrosis of the femoral head in patients treated with high-dose glucocorticoids for systemic rheumatic diseases.

  2009cites this paper
• Bisphosphonates in Patients with Glucocorticoids: Time for Implementation

  2009cites this paper
• Prevention of glucocorticoid-induced osteoporosis

  2009cites this paper
• Recurrent fractures in an elderly patient with systemic lupus erythematosus

  2009cites this paper
• Recent Advances in the Management of Steroid Induced Osteoporosis

  2008cites this paper
• Alendronate once weekly for the prevention and treatment of bone loss in Canadian adult cystic fibrosis patients (CFOS trial).

  2008cites this paper
• A Comparison of Calcium, Calcitriol, and Alendronate in Corticosteroid-Treated Premenopausal Patients with Systemic Lupus Erythematosus

  2008cites this paper
• Glucocorticoid‐induced osteoporosis

  2008cites this paper
• Alendronate Protects Premenopausal Women from Bone Loss and Fracture Associated with High-dose Glucocorticoid Therapy

  2008cites this paper